295 related articles for article (PubMed ID: 34962713)
1. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
[TBL] [Abstract][Full Text] [Related]
3. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
4. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
Hyeon J; Ahn S; Shin JH; Oh YL
Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
[TBL] [Abstract][Full Text] [Related]
5. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
6. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
[No Abstract] [Full Text] [Related]
7. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE
Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
Hall EA; Hartzband P; VanderLaan PA; Nishino M
Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
[TBL] [Abstract][Full Text] [Related]
9. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
Wu H; Zhang B; Cai G; Li J; Gu X
PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
[TBL] [Abstract][Full Text] [Related]
10. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
[TBL] [Abstract][Full Text] [Related]
12. The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio: a proposed performance measure for reporting in The Bethesda System for thyroid cytopathology.
Krane JF; Vanderlaan PA; Faquin WC; Renshaw AA
Cancer Cytopathol; 2012 Apr; 120(2):111-6. PubMed ID: 21919213
[TBL] [Abstract][Full Text] [Related]
13. Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF
Chirayath SR; Pavithran PV; Abraham N; Nair V; Bhavani N; Kumar H; Menon UV; Menon AS
Indian J Endocrinol Metab; 2019; 23(3):278-281. PubMed ID: 31641627
[TBL] [Abstract][Full Text] [Related]
14. Young investigator challenge: Atypia of undetermined significance in thyroid FNA: Standardized terminology without standardized management--a closer look at repeat FNA and quality measures.
Brandler TC; Aziz MS; Coutsouvelis C; Rosen L; Rafael OC; Souza F; Jelloul FZ; Klein MA
Cancer Cytopathol; 2016 Jan; 124(1):37-43. PubMed ID: 26765064
[TBL] [Abstract][Full Text] [Related]
15. [On-site fine-needle aspiration cytology of thyroid nodules. Quality assurance of the Bethesda System for Reporting Thyroid Cytopathology (2008)].
Bak M; Péter I; Nyári T; Simon P; Újlaky M; Boér A; Kásler M
Orv Hetil; 2015 Oct; 156(41):1661-6. PubMed ID: 26551169
[TBL] [Abstract][Full Text] [Related]
16. A Large Thyroid Fine Needle Aspiration Biopsy Cohort with Long-Term Population-Based Follow-Up.
Ng DL; van Zante A; Griffin A; Hills NK; Ljung BM
Thyroid; 2021 Jul; 31(7):1086-1095. PubMed ID: 33371796
[No Abstract] [Full Text] [Related]
17. Application of the Bethesda Classification for Thyroid Fine-Needle Aspiration: Institutional Experience and Meta-analysis.
Krauss EA; Mahon M; Fede JM; Zhang L
Arch Pathol Lab Med; 2016 Oct; 140(10):1121-31. PubMed ID: 27684984
[TBL] [Abstract][Full Text] [Related]
18. Fine needle aspiration of thyroid nodules in the pediatric population: a 12-year cyto-histological correlation experience at North Shore-Long Island Jewish Health System.
Lale SA; Morgenstern NN; Chiara S; Wasserman P
Diagn Cytopathol; 2015 Aug; 43(8):598-604. PubMed ID: 25728981
[TBL] [Abstract][Full Text] [Related]
19. Evaluating local thyroid cytopathology practices by molecular quality metrics: A multi-institutional study on 4651 FNAs with a focus on the role of the interventional cytopathologist.
Nacchio M; Palladino R; Vigliar E; Pisapia P; Salatiello M; Malapelle U; Porcelli T; Luongo C; Fonderico F; Masone S; Salvatore D; Troncone G; Bellevicine C
Cancer Cytopathol; 2023 Dec; 131(12):772-780. PubMed ID: 37635646
[TBL] [Abstract][Full Text] [Related]
20. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
